Dual Gene Therapy
Targeting Type 2 Diabetes and Obesity
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS